Ayesha Zia1, Joy Russell2, Ravi Sarode3, Surendranath R Veeram4, Shellie Josephs5, Kendra Malone6, Song Zhang7, Janna Journeycake8. 1. Division of Pediatric Hematology/Oncology; Children's Medical Center, United States; The University of Texas Southwestern Medical Center, United States. Electronic address: Ayesha.zia@utsouthwestern.edu. 2. Health Sciences Digital Library and Learning Center; The University of Texas Southwestern Medical Center, United States. 3. Department of Pathology; The University of Texas Southwestern Medical Center, United States. 4. Children's Medical Center, United States; Division of Pediatric Interventional Cardiology; The University of Texas Southwestern Medical Center, United States. 5. Children's Medical Center, United States; Division of Pediatric Interventional Radiology; The University of Texas Southwestern Medical Center, United States. 6. Children's Medical Center, United States. 7. The Department of Clinical Sciences; The University of Texas Southwestern Medical Center, United States. 8. Division of Pediatric Hematology/Oncology; Children's Medical Center, United States; The University of Texas Southwestern Medical Center, United States.
Abstract
BACKGROUND: Sequelae of venous thromboembolism (VTE) in children include recurrence, development of post thrombotic syndrome (PTS) when venous return from a limb is affected and chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism. Identification of laboratory-based risk factors may be useful for individualized risk assessment for VTE sequelae. Coagulation activation and inflammation may contribute to their pathophysiology. We performed a systematic review to investigate the association between biomarkers of coagulation activation, inflammation and fibrinolysis and adverse VTE outcomes in children and young adults. METHODS: A systematic search of electronic databases, PubMed (NIH), EMBASE (Ovid), Web of Science (Thompson Reuters), and SCOPUS (Elsevier) for studies published through November 2016 was conducted using "VTE" including MeSH terms for "coagulation activation," "inflammation" and "fibrinolysis," with no limit on publication date. A study was eligible for inclusion when it evaluated patients (< 21years) with VTE and biomarkers of coagulation activation, inflammation, and fibrinolysis and assessed for their association with development of adverse thrombotic outcomes. A modified Newcastle Ottawa Scale was applied to examine the quality of included studies. RESULTS: Our search strategy yielded 200 references. A total of 3 cohort studies representing 220 patients with VTE were included. Two authors independently assessed all references for inclusion. Three studies (2 prospective cohort and one mixed cohort study) were identified that reported on biomarkers of coagulation activation, inflammation and fibrinolysis, checked at least once after VTE diagnosis and assessed association with primary outcomes of recurrent VTE, PTS and CTEPH. Studies varied with regards to definition of outcomes, the type of biomarkers measured and time point of measurement. We were unable to meta-analyze results due to marked clinical heterogeneity and <3 studies available for each biomarker. Descriptively, a significant association was found for elevated plasma levels of FVIII and D-dimer for a compound outcome of PTS, recurrence and progression in one study, and positive lupus anticoagulant at DVT diagnosis and subsequent PTS by another study. No studies were found for CTEPH. CONCLUSIONS: Elevated D-dimer, FVIII and lupus anticoagulant show promise for predicting recurrent VTE and PTS in children and young adults. Further research is needed to elucidate whether these markers might be useful to predict development of adverse outcomes after VTE in children.
BACKGROUND: Sequelae of venous thromboembolism (VTE) in children include recurrence, development of post thrombotic syndrome (PTS) when venous return from a limb is affected and chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism. Identification of laboratory-based risk factors may be useful for individualized risk assessment for VTE sequelae. Coagulation activation and inflammation may contribute to their pathophysiology. We performed a systematic review to investigate the association between biomarkers of coagulation activation, inflammation and fibrinolysis and adverse VTE outcomes in children and young adults. METHODS: A systematic search of electronic databases, PubMed (NIH), EMBASE (Ovid), Web of Science (Thompson Reuters), and SCOPUS (Elsevier) for studies published through November 2016 was conducted using "VTE" including MeSH terms for "coagulation activation," "inflammation" and "fibrinolysis," with no limit on publication date. A study was eligible for inclusion when it evaluated patients (< 21years) with VTE and biomarkers of coagulation activation, inflammation, and fibrinolysis and assessed for their association with development of adverse thrombotic outcomes. A modified Newcastle Ottawa Scale was applied to examine the quality of included studies. RESULTS: Our search strategy yielded 200 references. A total of 3 cohort studies representing 220 patients with VTE were included. Two authors independently assessed all references for inclusion. Three studies (2 prospective cohort and one mixed cohort study) were identified that reported on biomarkers of coagulation activation, inflammation and fibrinolysis, checked at least once after VTE diagnosis and assessed association with primary outcomes of recurrent VTE, PTS and CTEPH. Studies varied with regards to definition of outcomes, the type of biomarkers measured and time point of measurement. We were unable to meta-analyze results due to marked clinical heterogeneity and <3 studies available for each biomarker. Descriptively, a significant association was found for elevated plasma levels of FVIII and D-dimer for a compound outcome of PTS, recurrence and progression in one study, and positive lupus anticoagulant at DVT diagnosis and subsequent PTS by another study. No studies were found for CTEPH. CONCLUSIONS: Elevated D-dimer, FVIII and lupus anticoagulant show promise for predicting recurrent VTE and PTS in children and young adults. Further research is needed to elucidate whether these markers might be useful to predict development of adverse outcomes after VTE in children.
Authors: N A Goldenberg; L R Brandão; J Journeycake; S R Kahn; P Monagle; S Revel-vilk; A Sharathkumar; A K C Chan Journal: J Thromb Haemost Date: 2012-03 Impact factor: 5.824
Authors: Magdalena L Bochenek; Nico S Rosinus; Mareike Lankeit; Lukas Hobohm; Felix Bremmer; Eva Schütz; Frederikus A Klok; Sven Horke; Christoph B Wiedenroth; Thomas Münzel; Irene M Lang; Eckhard Mayer; Stavros Konstantinides; Katrin Schäfer Journal: Thromb Haemost Date: 2017-02-02 Impact factor: 5.249
Authors: Neil A Goldenberg; Marco P Donadini; Susan R Kahn; Mark Crowther; Gili Kenet; Ulrike Nowak-Göttl; Marilyn J Manco-Johnson Journal: Haematologica Date: 2010-06-30 Impact factor: 9.941
Authors: Christopher Bombardier; Elizabeth Villalobos-Menuey; Katherine Ruegg; William E Hathaway; Marilyn J Manco-Johnson; Neil A Goldenberg Journal: Thromb Res Date: 2012-04-30 Impact factor: 3.944
Authors: Edith M Roumen-Klappe; Martin den Heijer; Stan H M van Uum; Johanna van der Ven-Jongekrijg; Fedde van der Graaf; Hub Wollersheim Journal: J Vasc Surg Date: 2002-04 Impact factor: 4.268
Authors: Prakash Saha; Julia Humphries; Bijan Modarai; Katherine Mattock; Matthew Waltham; Colin E Evans; Anwar Ahmad; Ashish S Patel; Sobath Premaratne; Oliver T A Lyons; Alberto Smith Journal: Arterioscler Thromb Vasc Biol Date: 2011-03 Impact factor: 8.311